ORTICOSTEROIDS are commonly administered, often for prolonged periods, to patients with brain tumors for the symptomatic relief of cerebral edema. Common consequences of long-term corticosteroid therapy include centripetal obesity with cushingoid facies, abdominal striae, disordered sleep patterns, and neuropsychiatric disturbances ranging from mild behavioral changes to major psychoses. [10] [11] [12] 25, 33 Adrenal glucocorticoids are known to affect cell glucose utilization throughout the body and studies have shown there is an effect on brain-glucose utilization, although the mechanism of neuropsychiatric abnormalities in patients with long-term corticosteroid therapy is unclear. 26, 33 In preliminary work 18 we noted by using positron emission tomography (PET) with the glucose analog [ 18 F]fluoro-2-deoxyglucose (FDG) that there was a marked reduction in cerebral glucose utilization in patients with Cushing's disease who had high circulating levels of endogenous corticosteroids.
ORTICOSTEROIDS are commonly administered, often for prolonged periods, to patients with brain tumors for the symptomatic relief of cerebral edema. Common consequences of long-term corticosteroid therapy include centripetal obesity with cushingoid facies, abdominal striae, disordered sleep patterns, and neuropsychiatric disturbances ranging from mild behavioral changes to major psychoses. [10] [11] [12] 25, 33 Adrenal glucocorticoids are known to affect cell glucose utilization throughout the body and studies have shown there is an effect on brain-glucose utilization, although the mechanism of neuropsychiatric abnormalities in patients with long-term corticosteroid therapy is unclear. 26, 33 In preliminary work 18 we noted by using positron emission tomography (PET) with the glucose analog [ 18 F]fluoro-2-deoxyglucose (FDG) that there was a marked reduction in cerebral glucose utilization in patients with Cushing's disease who had high circulating levels of endogenous corticosteroids.
In the present study our hypothesis was that exogenous corticosteroids reduce cerebral glucose metabolism (CMR glu ). Thus we measured glucose metabolism, using FDG-PET, in patients with brain tumors who displayed cushingoid symptoms from prolonged corticosteroid administration. However, because of potential effects of the brain tumor on ipsilateral cerebral structures and the premise that an effect from corticosteroids would be generalized, we measured glucose metabolism in the uninvolved cerebral hemisphere. In addition, we compared values for glucose metabolism in the cushingoid patients to those obtained in treated and untreated brain tumor patients who were not cushingoid and to values obtained for normal subjects because of the potential for confounding variables such as effects of radiotherapy, anticonvulsant medication, and transhemispheric functional disconnection in patients.
Clinical Material and Methods

Patient Population
All patients were studied under protocols approved by committees of the National Institute of Neurological Disorders and Stroke and the Clinical Center of the National Institutes of Health. Informed consent was obtained from all subjects prior to their participation in the studies.
All patients had a unilateral brain tumor that was confirmed by magnetic resonance (MR) imaging. Patients were excluded if: 1) the cerebral hemisphere contralateral to the tumor was edematous or atrophic, had abnormal signal intensity on T 1 -or T 2 -weighted sequences, or was compressed by mass effect; and 2) the corpus callosum was involved by tumor or edema. Pathological diagnoses of the cerebral astrocytomas were based on the World Health Organization (WHO) classification 51 and, for this paper, patients were separated into categories of lowgrade astrocytoma (LGA), anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and oligodendroglioma.
Clinical protocols and data for the patients were as follows. Patients were divided into three groups: A, B, and C. Group A consisted of patients with cushingoid facies (confirmed by the patient and a close relative) who had been taking oral corticosteroids (dexamethasone) for at least 2 months. There were seven men and nine women in this group, with a mean age of 42 years (range 24-61 years). All patients complained of significant weight gain after the institution of dexamethasone; the majority developed striae of the abdomen and upper thighs and two patients had multiple vertebral body-crush fractures. Methods of diagnosis were surgical resection in two cases, partial surgical resection in seven, open biopsy in five and stereotactic biopsy in two cases. Pathological diagnoses were GBM in six patients, AA in eight, anaplastic oligodendroglioma in one, and LGA in one patient. Tumors involved a single cerebral lobe in seven patients (parietal in four patients, temporal in one, frontal in one, and occipital in one). The frontoparietal lobes were involved in three, temporoparietal lobes in two, and parietooccipital in two. In two patients the tumor was restricted to the thalamus. All but one patient had been treated with combinations of radiation and chemotherapy. Conventional external-beam radiotherapy to 60 Gy was administered: 1) to three patients as a single treatment modality; 2) in addition to systemic chemotherapy in three patients; 3) in addition to intraarterial chemotherapy in one patient; and 4) in combination with gamma knife (one patient), radiosurgery (one patient) and interstitial brachytherapy (IB) (one patient). Two patients were treated with external-beam radiotherapy to 70 Gy and three patients received external-beam radiotherapy (30 to 50 Gy) and IB. Eight patients in Group A had more than one FDG-PET scan and three of these patients had three PET studies. Six of these eight patients were not taking dexamethasone at the time of the first PET scan. The total dexamethasone dose was difficult to estimate accurately because of slight variations in dosage related to symptoms. The daily dose of dexamethasone on the day of the first PET scan with the patient "on corticosteroids" ranged from 4 to 32 mg, with an average dosage of 17.8 mg dexamethasone per day.
In Group B, patients with brain tumors had been treated with radiation therapy but had never taken dexamethasone or had not used it for at least 4 months prior to the PET scan. The patients in this group consisted of 13 men and 3 women with a mean age of 43 years (range 26-63 years). Methods of diagnosis were partial surgical resection in 10 cases, open biopsy in three, and stereotactic biopsy in three cases. Pathological diagnoses were GBM in two patients, AA in nine, and LGA in five. Gliomas were limited to a single cerebral lobe in 13 patients (frontal in seven patients, temporal in three, occipital in two, and parietal in one) or the thalamus in one patient. Frontoparietal and temporoparietal lobes were involved in two others. All patients had been treated with externalbeam radiotherapy in doses varying from 54 to 70 Gy with four patients receiving less than 60 Gy. In addition, one patient had external-beam radiotherapy (60 Gy) plus IB (60 Gy) and one patient had external-beam radiotherapy (60 Gy) and a radiosurgery boost.
Group C was composed of patients who had not been treated with radiation or chemotherapy at the time of the PET study. There were eight men and five women in this group with a mean age of 43 years (range 26-66 years). Methods of diagnosis were partial surgical resection in five cases, open biopsy in two, and stereotactic biopsy in six. Pathological diagnoses were GBM in one patient, AA in two, LGA in seven, and oligodendroglioma in three patients. In five cases the tumor was restricted to the frontal lobe, in three cases to the parietal lobe, and in two cases to the temporal lobe. The frontoparietal lobes were involved in three cases. One patient had begun dexamethasone therapy (16 mg/day) the day prior to the PET scan but treatment was stopped 12 hours before commencing the PET study.
The patients were matched as closely as possible for tumor size and location across the three groups. In two patients with LGA (one each from Groups A and B) the clinical course was that of a high-grade glioma and both patients had foci of markedly increased glucose metabolism in the tumor on FDG-PET scans, suggesting that although pathology indicated low-grade tumors, the pathological assessment was inaccurate because of sampling error. No patient had corticosteroid-induced hyperglycemia. Forty-one of 45 patients were taking regular anticonvulsant medication. In the majority of cases this was used as monotherapy with phenytoin, carbamazepine, sodium valproate, or phenobarbital. Ten patients were taking two anticonvulsants for seizure control. Two patients in Group A and one patient each in Groups B and C were not taking anticonvulsant medication.
Neuroimaging Studies
Two tomographs were used for the study. All but two of the FDG-PET studies were performed using a 15-section tomograph (PC 2048-15B; Scanditronix, Uppsala, Sweden) with 6-mm inplane resolution and 6-mm section thickness. Two patients had a second PET study performed using a seven-slice scanner (PC 1024-7B, Scanditronix) with 6-to 7-mm inplane resolution and 10.5-mm slice thickness. Our FDG-PET technique has been described in detail elsewhere. 19 Patients fasted for at least 6 hours before the study. The FDG (185 MBq) was injected via a peripheral intravenous line. Blood was sampled at timed intervals throughout the study from a cannula placed in the radial artery at the wrist to determine the input function. For five studies the input function was derived from "arterialized-venous" blood samples drawn from a venous cannula placed in the dorsum of a heated hand. 39 Emission scans were performed after a 30-minute uptake period and interleaved to cover the entire brain. The study duration was 70 minutes. Measured attenuation correction was performed for each study. Imaging planes were oriented parallel to the canthomeatal line. Subjects' eyes and ears were patched and their heads immobilized by a thermoplastic mask molded to the contours of the face for the duration of the study. The FDG-PET examination was conducted in a quiet, dimly lighted room. All data were corrected for scatter and random coincidences. Glucose metabolic rates were calculated using a modification 9 of the Sokoloff three-compartment model 43 with the following gray matter rate constants: k 1 = 0.1020; k 2 = 0.1300; k 3 = 0.0620; and k 4 = 0.0068. 40 The lumped constant value was 0.4180. 39 Serum blood glucose level was measured prior to and during the PET scan.
With respect to the brain tumor, glucose metabolism was measured in the contralateral cerebral hemisphere, ipsilateral cerebellar hemisphere, and midline posterior fossa structures (brainstem and cerebellar vermis). The ipsilateral rather than contralateral cerebellar hemisphere was analyzed to evaluate if the steroid effect was generalized and because of the likelihood of the tumor producing crossed cerebellar glucose hypometabolism, so-called crossed cerebellar diaschisis, in the contralateral cerebellar hemisphere. 5, 17 Readings were taken from circular regions of interest (ROIs) measuring 8 mm in diameter (12 pixels). The ROIs were positioned to sample clearly identifiable functional anatomical landmarks on the PET scans. There were 100 circular and one irregular ROIs. Readings were taken with the circular ROIs in the frontal, parietal, temporal, and occipital lobes; the precuneus; deep nuclei (caudate, putamen, thalamus); cerebellar hemispheres; cerebellar vermis; and brainstem. Cortical ROIs did not overlap and were equally spaced to cover the cortical mantle. Thus the main cerebral lobes, rather than discrete gyri, were analyzed with the aid of an atlas. 4 The irregular ROI was drawn in the white matter of the centrum semiovale above the bodies of the caudate nuclei. Tissue sections used in the analysis were selected in advance by the senior investigator (M.J.F.). Nineteen normal volunteers, eight men and 11 women with a mean age of 42 years (range 21-67 years) were also included in the study as a control group. In the case of normal volunteers glucose metabolism was assessed for both sides of the brain and average values were calculated for each anatomical area using the same ROI template. The regional analysis was performed by the same investigator (L.A.).
Magnetic resonance imaging studies were obtained in all patients within a few days of the FDG-PET study. The T 1 -and T 2 -weighted MR sequences taken after intravenous administration of gadolinium-DTPA (gadopentetate dimeglumine, 0.1 mmol/kg; Magnevist, Berlex Laboratories, Cedar Knolls, NJ) were obtained at 0.5-tesla (Picker Vista HP, Highland Heights, OH). All MR imaging studies were acquired from the same plane as the FDG-PET scan using Vitamin E capsules, taped to the outer canthus of the eye and the external auditory canal, as external reference markers. Typical pulse sequences were: T 1 = repetition time (TR) 600 msec, echo time (TE) 16 msec; T 2 = TR 2583 msec, TE 40/100 msec. The MR imaging studies were evaluated for tumor progression and evidence of cerebral edema or atrophy in the hemisphere contralateral to the tumor by one of the investigators (M.J.F.) and independently by a neuroradiologist in the Diagnostic Radiology Department, Clinical Center, National Institutes of Health.
Statistical Analysis
Mean values for glucose metabolism were compared in the four groups for each anatomical region using the Kruskal-Wallis test followed by direct comparisons between the groups. 13 For normal volunteers the mean value for glucose metabolism for the two hemispheres was used for each anatomical region. In the eight Group A patients who had serial scans, the first scan performed with the patient taking dexamethasone was used for the analysis between groups.
Results
Mean regional CMR glu for normal volunteers and the three patient groups are shown in Table 1 . Regional CMR glu was significantly lower in Group A compared to normal volunteers (p Ͻ 0.001) in all regions analyzed. Group A patients also had reduced CMR glu throughout the supratentorial cortex (frontal, temporal, parietal, and occipital lobes and precuneus; p Ͻ 0.001), ipsilateral cerebellar cortex (p Ͻ 0.01), thalamus (p Ͻ 0.001 for Group B and p Ͻ 0.05 for Group C) and basal ganglia (p Ͻ 0.001) compared to Groups B and C. Figure 1 shows scatter plots of single values from each patient for the cerebrum, parietal lobe, and cerebellar hemispheres. Scatter plots for the individual anatomical regions showed a similar pattern. For all regions there were no statistical differences in CMR glu between those patients who were treated with modalities other than surgery (Group B) and those who were untreated (Group C). Groups B and C had lower glucose metabolism (p Ͻ 0.05) than normal volunteers in all regions except the frontal lobe and precuneus. However, as can be seen from the scatter plots in Fig. 1 , there is overlap between Groups B and C and the normal volunteers. In the case of the cerebellum, if one excludes the single outlier in the normal volunteers, there is very little difference between Groups B, C, and the normal volunteers. Glucose metabolism in deep nuclei (caudate, putamen, and thalamus) was significantly lower for Group C (p Ͻ 0.05) compared to normal volunteers, whereas for Group B only the putamen showed lower glucose metabolism when compared to normals (p Ͻ 0.05).
Mean CMR glu for patients in Group A who had serial PET studies are shown in Table 2 . Six patients (Cases 4, 7, 9, 12, 13, and 16) were not taking corticosteroids at the time of their first PET scan. Four of these six patients had recently been diagnosed. In all but two patients (Cases 8 and 10) there was a progressive reduction in CMR glu . In Case 8 there was minimal change in CMR glu over a 4-month period. However, the patient in Case 10 showed a 40% increase in CMR glu over a 7-month period, which coincided with a reduction in dexamethasone dosage from 26 mg per day to 4 mg per day because of the development of multiple vertebral body-crush fractures. In Fig. 2 representative FDG-PET scans are shown for Case 7; the scans were obtained before the patient began to take dexamethasone and again two months later when the patient was taking 32 mg dexamethasone per day. Enhanced MR images (Fig. 3 ) obtained in Case 7 within 1 week of each of these FDG-PET scans show the development of an area of gadolinium enhancement not evident on the first MR study, which involves the white matter of the right frontal lobe and adjacent gray matter. There is no evidence of cerebral atrophy between MR imaging studies. In two of the three patients who had three studies, dexamethasone dosage increased between Study 2 and Study 3. In Case 4, the dexamethasone dosage remained at 12 mg per day between Study 2 and Study 3.
Cerebral atrophy was not reported in the hemisphere contralateral to the tumor in any patient on MR imaging. However, in the patients in Group A who had serial studies minimal cerebral atrophy consisting of widening of the cerebral sulci was noted in three patients (Cases 10, 12, and 16).
Discussion
The main findings of this study are: 1) CMR glu is markedly reduced in patients with brain tumor who are treated with chronic oral corticosteroid therapy. Although only observed in a single case, a reduction in corticosteroid dosage was associated with an increase in CMR glu . 2) A mild reduction in contralateral CMR glu is also seen in patients with brain tumor who are not taking corticosteroid therapy. These in vivo human data indirectly support earlier in vivo animal work by Kadekaro, et al., 26 who reported an acute increase in cerebral glucose utilization after adrenalectomy in rats, using [ 14 C]2-deoxyglucose autoradiography, and an in vitro study in which corticosterone and dexamethasone were shown to inhibit glucose uptake in cultured hippocampal neurons and glial cells with an apparently dose-dependent receptor-mediated action. 23 However, a number of other factors may potentially affect glucose metabolism in the contralateral hemisphere in patients with brain tumors: direct tumor infiltration, functional disconnection (diaschisis), cerebral atrophy, radiation therapy, and anticonvulsant medication. Direct tumor infiltration of the opposite cerebral hemisphere would reduce cortical glucose metabolism by compression of cortical gray matter or by deafferentation through involvement of white matter tracts. Although microscopic involvement of the opposite cerebral hemisphere could not be excluded, there was no clinical or MR imaging evidence (gadolinium enhancement or increased T 2 signal intensity) indicating involvement. Thus we believe that tumoral extension is not a likely mechanism for our findings.
Von Monakow 47 first introduced the concept of "diaschisis." Although there has been controversy regarding its definition, 48 the currently accepted definition of diaschisis encompasses ". . . all remote effects of acute and chronic cerebral injury." 2, 30 Diaschitic involvement of the contralateral cerebellar hemisphere, with respect to a supratentorial lesion, and the ipsilateral and contralateral cerebral hemispheres are now generally recognized. 5, 16, 17, 37 Most studies of transhemispheric diaschisis have used the model of cerebral ischemia as the mechanism of cerebral injury in patients with stroke or a variety of methods to induce ischemia 2 involvement of the corpus callosum is critical to diaschisis' development. 3, 50 These studies show conflicting data depending on the length of time after injury the study was performed. 21, 49 In the chronic situation, mimicked by brain tumors, little change in contralateral glucose utilization is reported in animal studies. 15, 20, 27 Data on patients with brain tumor are scarce, but Beaney and colleagues 6 reported decreased oxygen extraction and cerebral blood flow ( 15 O-PET) in the contralateral hemisphere of brain-tumor patients who were not taking corticosteroids. They also noted that this reduction was partially reversed by decompressive surgery. However, in most of their patients, the tumors were large and there was considerable mass effect with midline shift implicating direct contralateral hemispheric compression. In addition, four of the seven patients who were studied postoperatively were taking dexamethasone at the time of the PET study. In our patient groups we excluded patients with evidence of midline shift or involvement of the corpus callosum and we attempted to match tumor sites and sizes for the three groups. The definite but small difference in CMR glu between Groups B, C, and normal volunteers suggests that transhemispheric diaschisis may have contributed. However, we believe that diaschisis alone does not account for the marked difference between Group A and Groups B and C. Furthermore, the images depicted in Fig. 2 indicate a generalized reduction in CMR glu and the serial FDG-PET studies obtained in Case 10 (Table 2) argue against progressive functional disconnection as the sole explanation.
Cerebral atrophy is known to occur after prolonged steroid treatment in patients with a variety of systemic diseases and also in patients with Cushing's disease. 7, 31, 34 Some data indicate that this effect is reversible and that the atrophy reflects reduced cell volume rather than cell loss. 22 Cerebral atrophy introduces a partial volume error into PET measurements. In the absence of quantitative volumetric MR measurements, we cannot exclude mild cerebral atrophy not visible on qualitative assessment of MR image sections, but we believe this could only account for a small part of the marked decrease in glucose utilization seen in Group A patients.
Concerning possible effects of radiation treatment, no significant differences were found between the two groups of patients not taking steroids, with and without radiation therapy, suggesting that in our patients, radiation treatment per se did not affect glucose metabolism in the contralateral brain to the extent observed in patients taking dexamethasone.
Anticonvulsant medication affects CMR glu 14,42 and Theodore and associates [44] [45] [46] demonstrated that barbiturates and, to a lesser extent, phenytoin and carbamazepine reduce CMR glu with FDG-PET. Forty-one of our 45 patients were taking various combinations of anticonvulsant medication at the time of the PET study but the anticonvulsant medication was uniformly distributed between the groups. In addition, the patient in Case 10, in whom CMR glu increased after dexamethasone dosage was reduced from 26 mg to 4 mg per day, continued to take the same dose of phenobarbital during and between the two PET studies. Thus, although anticonvulsant medication may contribute to the difference between values for glucose metabolism in patients and normal volunteers, for the patient groups this effect should be uniform.
Finally, measurements of glucose metabolism may be influenced by changes in values of kinetic rate constants between the three compartments or changes in the lumped constant. 40, 43 Leenders and colleagues 28 reported that acute effects of steroid administration include a global reduction in cerebral blood flow and blood volume and an increased oxygen extraction ratio in the brain, but no overall changes in oxygen utilization. Furthermore, blood-brain barrier permeability appears to be decreased by steroid treatment. 24 The Sokoloff method minimizes the potential effects of these modifications, and although we cannot completely exclude effects on rate constants, the observed (Fig. 2 upper) show signal hypointensity in white matter of right frontal lobe. Right: Images obtained at the time of the patient's second FDG-PET scan (Fig. 2 lower) . In the white matter of the right frontal lobe and adjacent cingulate cortex there is heterogeneous enhancement consistent with recurrent tumor.
changes in glucose utilization rates in patients on steroid therapy should reflect a true decrease in the metabolic rate. 43 We can only speculate as to the mechanism of the dexamethasone-induced reduced glucose metabolism. Dexamethasone may have a direct effect on glucose utilization within neurons and neuroglia or there may be a direct effect on glucose transport via glucose transporters. Recently, five functional facilitative glucose transporters have been cloned and identified 8, 32, 38 and Olgemöller, et al., 35 have postulated that cortisol has a direct effect on the endothelial transport of glucose. However, glucocorticoid receptors are widely distributed in glia and neurons, which may also explain the generalized metabolic effect. 1, 29 Sapolsky and colleagues 36, 41 demonstrated in vitro and autoradiographically that glucocorticoids have a selective action on the hippocampus and the authors suggest that this action may relate to several neuropsychiatric problems. We did not specifically measure glucose metabolism in the hippocampus because the small size of the relevant structures (dentate gyrus and subiculum) are beyond the resolution of the PET tomographs we used in this study. Despite this our results indicate that the effect of dexamethasone is global rather than localized.
